DFSVX
Price
$59.85
Change
+$0.57 (+0.96%)
Updated
Jun 2 closing price
Net Assets
18.72B
RSQCX
Price
$15.10
Change
+$0.06 (+0.40%)
Updated
Jun 2 closing price
Net Assets
472.52M
Interact to see
Advertisement

DFSVX vs RSQCX

Header iconDFSVX vs RSQCX Comparison
Open Charts DFSVX vs RSQCXBanner chart's image
DFSVX vs RSQCX Comparison Chart in %
View a ticker or compare two or three
VS
DFSVX vs. RSQCX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DFSVX is a Buy and RSQCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
DFSVX has more cash in the bank: 18.7B vs. RSQCX (473M). DFSVX pays higher dividends than RSQCX: DFSVX (1.51) vs RSQCX (1.32). DFSVX was incepted earlier than RSQCX: DFSVX (33 years) vs RSQCX (23 years). RSQCX (2.45) is less costly to investors than DFSVX (0.31). RSQCX is a more actively managed with annual turnover of: 12.00 vs. DFSVX (7.00). DFSVX has a lower initial minimum investment than RSQCX: DFSVX (0) vs RSQCX (2000). DFSVX annual gain was more profitable for investors over the last year : 37.29 vs. RSQCX (22.94). DFSVX return over 5 years is better than : 36.39 vs. RSQCX (-18.09).
DFSVXRSQCXDFSVX / RSQCX
Total Expense Ratio0.312.2414%
Annual Report Gross Expense Ratio0.312.4513%
Fund Existence33 years23 years-
Gain YTD16.31918.99186%
Front LoadN/AN/A-
Min. Initial Investment02000-
Min. Initial Investment IRAN/AN/A-
Net Assets18.7B473M3,953%
Annual Yield % from dividends1.511.32114%
Returns for 1 year37.2922.94163%
Returns for 3 years61.264.431,384%
Returns for 5 years36.39-18.09-201%
Returns for 10 years101.56-11.75-864%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRNS90.562.47
+2.80%
Transcat
ZGN14.600.11
+0.76%
Ermenegildo Zegna NV
DOUG1.77-0.02
-1.12%
Douglas Elliman
MDLN33.19-2.56
-7.16%
Medline Inc
ERNA8.07-1.04
-11.46%
Ernexa Therapeutics Inc.